Trial Profile
A phase I clinical trial of radiolabeled immunotherapy with humanized LL2 [epratuzumab Y-90] in patients with refractory or recurrent non-Hodgkin's lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Epratuzumab Y-90 (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 08 Jan 2008 Status changed from in progress to discontinued.
- 01 Oct 2005 New trial record.